An ‘insane’ calculus: A pharma company raised price for a rare disease drug 150% to cover Medicaid rebates

Taking stock of the drug industry, from the lab to the medicine chest

April 22, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | An 'insane' calculus: A pharma company raised price for a rare disease drug 150% to cover Medicaid rebates The CEO of Eton Pharmaceuticals says the drug will still be a "barely profitable" product in the U.S. and described the overall calculus as "insane." By Ed Silverman STAT+ | FDA Commissioner Marty Makary announces three new hires in leadership team The hires begin to fill the leadership void caused by the departures of high-level officials recently. Some left by choice, while others were let go. By Lizzy Lawrence and Brittany Trang STAT+ | Biotech entrepreneur Sam Waksal accused of 'reckless conduct' in new lawsuit A trustee for Equilibre Biopharmaceuticals alleges that the former CEO gave an ill child a substance not approved for human use, among other charges. By Adam Feuerstein Ben Curtis/AP STAT+ | NIH director calls Trump's anti-DEI orders 'misunderstood,' downplays reorganization plans Director says he "wouldn't have accepted the job" if Trump orders were meant to stop research advancing health of minority populations By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser